ALOPECIA areata (AA) is a
common autoimmune disease
resulting from damage of the hair
follicle by T cells, resulting in hair
loss.
In a new study out of Columbia
University, New York and published
in Nature Medicine, patients
treated with oral ruxolitinib, an
inhibitor of janus kinase (JAK1 and
JAK2), achieved near-complete hair
regrowth within five months of
treatment.
Ruxolitinib is marketed in
Australia by Novartis as Jakavi, is
not approved for AA treatment but
is indicated for the treatment of
certain types of myelobrosis under
specific conditions.
To read the study CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 20 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Aug 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.